Abstract: The present invention relates to a drug delivery device for mixing and delivering a drug by injection. The device includes a housing having a first port or opening therein that receives a first container that contains a fluid or powdered drug, for example a lyophilized drug. The housing can also include a second port or opening that receives a second container that contains a fluid to be mixed with the drug to form an injectable fluid. The device includes a manifold having a channel that fluidly connects the first and second containers. A penetrating membrane such as a needle is used to inject the drug into a patient which is in fluid communication with the first container. The needle is movable from a storage position in the housing to an injection position extending through the housing.
Type:
Application
Filed:
September 23, 2002
Publication date:
January 30, 2003
Applicant:
Elan Pharma International Limited
Inventors:
Gilad Lavi, Gil Ygal, Israil Tsals, Joseph Gross
Abstract: A drug delivery device having a base member defining a skin-contacting surface, a syringe serving as a reservoir for the drug, and means for expelling drug from the syringe. The syringe is connected to the base member such that the longitudinal axis of the syringe is substantially parallel to the skin surface. A delivery needle is in communication with the syringe. The needle has an angled bend which directs the tip of the needle substantially perpendicular to the skin-contacting surface. In use, the tip of the needle is adapted to penetrate the skin of the subject.
Abstract: A system for milling at least one material, e.g., a drug. The system includes a milling apparatus and at least one milling medium. The milling apparatus includes a chamber having a rotary milling head located in it. The milling head is rotated within the chamber by a magnetic drive system.
Abstract: A mechanism and method for preventing premature activation of an action includes a safety device. The safety device includes a housing that is arranged to enable such an action when the housing is in a desired orientation (e.g., horizontal, vertical). The housing includes a bowl having a concave cavity, a ball located in the cavity and a trigger having an actuator and a sleeve arranged to slide about the ball when the ball is in a predetermined position of the cavity to move the actuator and initiate the action.
Abstract: The present invention relates to a drug delivery device for mixing and delivering a drug by injection. The device includes a housing having a first port or opening therein that receives a first container that contains a fluid or powdered drug, for example a lyophilized drug. The housing can also include a second port or opening that receives a second container that contains a fluid to be mixed with the drug to form an injectable fluid. The device includes a manifold having a channel that fluidly connects the first and second containers. A penetrating membrane such as a needle is used to inject the drug into a patient which is in fluid communication with the first container. The needle is movable from a storage position in the housing to an injection position extending through the housing.
Type:
Grant
Filed:
November 12, 1999
Date of Patent:
November 12, 2002
Assignee:
Elan Pharma International Limited
Inventors:
Gilad Lavi, Gil Yigal, Izrail Tsals, Joseph Gross
Abstract: The present invention related to a drug delivery device for mixing and delivering a drug by injection. The devices includes a housing having a first port or opening therein that receives a first container that contains a fluid or powdered drug, for example, a lyophilized drug. The housing can also include a second port or opening that receives a second container that contains a fluid to be mixed with the drug to form an injectable fluid. The device includes a manifold having a channel that fluidly connects the first and second containers. A penetrating membrane such as a needle is used to inject the drug into a patient which is in fluid communication with the first container. The needle is movable from a storage position in the housing to an injection position extending through the housing.
Type:
Application
Filed:
February 7, 2002
Publication date:
September 5, 2002
Applicant:
ELAN PHARMA INTERNATIONAL LIMITED
Inventors:
Gilad Lavi, Gil Ygal, Izrail Tsals, Joseph Gross
Abstract: Particulate crystalline therapeutic substances are formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the mucosal membranes to provide extended therapeutic effect.
Type:
Grant
Filed:
March 11, 1997
Date of Patent:
August 13, 2002
Assignee:
Elan Pharma International Limited
Inventors:
Gary G. Liversidge, W. Mark Eickhoff, Kathleen J. Illig, Pramod Sarpotdar, Stephen B. Ruddy
Abstract: A small-scale or micro media-mill and a method of milling materials or products, especially pharmaceutical products, use a dispersion containing attrition milling media and the product to be milled. The milling media can be polymeric, formed of polystyrene or cross-linked polystyrene, having a nominal diameter of no greater than 500 microns. Other sizes include 200 microns and 50 microns and a mixture of these sizes. The mill has a relatively small vessel having an opening, an agitator, a coupling, and a motor. The agitator can have a rotor and a shaft extending therefrom. The rotor can be cylindrical or have other configurations, and can have tapered end surfaces. The coupling can close the vessel opening, or attaching the coupling to the motor can close the opening. The coupling has an opening through which the rotor shaft extends into the motor. A sealing mechanism, such as a mechanical or lip seals the shaft while permitting the rotor shaft to rotate.
Type:
Grant
Filed:
May 31, 2000
Date of Patent:
August 13, 2002
Assignee:
Elan Pharma International Limited
Inventors:
Robert Gary Reed, David A. Czekai, H. William Bosch, Niels Peter Ryde, Tuula Ryde
Abstract: The present invention relates to a drug delivery device for mixing and delivering a drug by injection. The device includes a housing having a first port or opening therein that receives a first container that contains a fluid or powdered drug, for example a lyophilized drug. The housing can also include a second port or opening that receives a second container that contains a fluid to be mixed with the drug to form an injectable fluid. The device includes a manifold having a channel that fluidly connects the first and second containers. A penetrating membrane such as a needle s used to inject the drug into a patient which is in fluid communication with the first container. The needle is movable from a storage position in the housing to an injection position extending through the housing.
Type:
Grant
Filed:
November 12, 1999
Date of Patent:
April 2, 2002
Assignee:
Elan Pharma International Limited
Inventors:
Gilad Lavi, Gil Yigal, Izrail Tsals, Joseph Gross
Abstract: Nanoparticulate compositions comprising an insoluble organic drug and at least one polyethylene glycol-derivatized lipid adsorbed on the surface of the drug are described. The polyethylene glycol-derivatized lipid can be a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, or a mixture thereof The compositions have an effective average particle size of less than about 1 micron. The invention also describes methods of making and using such compositions.
Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors are described.
Type:
Grant
Filed:
January 6, 1999
Date of Patent:
April 24, 2001
Assignee:
Elan Pharma International Limited
Inventors:
Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu
Abstract: The invention is directed to a device for delivering a pharmaceutically active compound or cosmetic substance to a subject comprises a flexible substrate sheet attached to an electronic controller. The controller is provided with a pair of electrical contacts on the underside thereof and is adhered to the sheet by means of a pair of strips of electrically conductive adhesive. The underside of the sheet is printed in two halves with electrically conductive ink to provide a pair of electrodes separated by an insulating barrier. A protuberance extends from each electrode and is folded onto the top of the sheet such that the contacts of the controller are adhered in electrical connection with the protuberances and thus also with the electrodes. The use of an adhesive to connect a controller in electrical communication with the electrodes enables an extremely simple construction of delivery device to be achieved.
Abstract: Described are an injectable formulation of nanoparticulate naproxen that produces minimal or no pain or burning sensation upon administration, and methods of making and using such a formulation. The injectable formulation comprises nanoparticulate naproxen having a povidone polymer adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 600 nm.
Abstract: A process for making a granulate composition suitable to the preparation of an oral solid form that can disintegrate rapidly inside the buccal cavity is provided as well as the granulate compositions and obtained.
Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HV-2) protease inhibitors are described.
Type:
Grant
Filed:
January 6, 1999
Date of Patent:
May 30, 2000
Assignee:
Elan Pharma International Limited
Inventors:
Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu
Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increase rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors are described.
Type:
Grant
Filed:
July 9, 1997
Date of Patent:
April 4, 2000
Assignee:
Elan Pharma International Limited
Inventors:
Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu